Global Conjugated Monoclonal Antibodies Market Top Major Players 2024 , Forecast To 2033
7 Mar, 2024
The conjugated monoclonal antibodies market has seen strong growth, from $10.9 billion in 2023 to $11.48 billion in 2024, with a CAGR of 5.3%. This growth is fueled by factors like increasing cancer prevalence and government support. The market is expected to continue growing, reaching $14.64 billion by 2028, driven by factors such as increased healthcare access and demand for minimally invasive procedures, alongside trends like advances in drug delivery and personalized medicine.
Global Conjugated Monoclonal Antibodies Market Key Driver
The therapeutic potential of conjugated monoclonal antibodies is expected to drive demand in the conjugated monoclonal antibodies market (8). With antibody-drug conjugates playing a crucial role in cancer treatment, their increased use is driving market growth, particularly in the cancer therapeutics sector.
Get A Free Sample Of The Global Conjugated Monoclonal Antibodies Market ReportGlobal Conjugated Monoclonal Antibodies Market Segments
The conjugated monoclonal antibodies market covered in this report is segmented –
1) By Drugs: Adcetris, Kadcyla
2) By Technology: Cleavable Linker, Non-cleavable Linker
3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Other Applications
By Geography: The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the conjugated monoclonal antibody market in 2023. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Conjugated Monoclonal Antibodies Industry Players
Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc.; Takeda Pharmaceuticals Industries Ltd.; Daiichi Sankyo Company Limited; Actinium Pharmaceutical; Nordic Nanovector Inc.; Spectrum Pharmaceuticals Inc.; AbbVie Inc.; Bayer AG; AstraZeneca plc; Novartis AG; Amgen; Celgene; Genentech; Emergent BioSolutions; Genzyme; Incyte Corporation; Kite Pharma; MorphoSys AG; Regeneron Pharmaceuticals; Seattle Genetics
Get The Full Global Conjugated Monoclonal Antibodies Market Report
Conjugated Monoclonal Antibodies Market Overview
Conjugated monoclonal antibodies refer to a compound formed from a monoclonal antibody that has been chemically coupled to a medication. The monoclonal antibody binds to particular proteins or receptors that are present on particular cell types, such as cancer cells. The associated medicine enters these cells, kills them, and leaves the rest of the cells alone.